Search
Lisinopril
go.drugbank.com/drugs/DB00722ApprovedInvestigational[A184844] Lisinopril was granted FDA approval on 29 December 1987.[L8384] … [A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.
Mixtures: LISINOPRIL 1A PLUS 10/12.5, LISINOPRIL 1A PLUS 10/12.5Categories: Compounds used in a research, industrial, or household settingMecasermin
go.drugbank.com/drugs/DB01277ApprovedInvestigationalMecasermin contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1)[FDA Label]. … IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons.
Pentetic acid
go.drugbank.com/drugs/DB14007ApprovedInvestigational[A32501] It is currently considered, in all the dosage forms, as a member of the list of approved inactive ingredients for drug products by the FDA. … [L2242] DPTA was developed by the pharmaceutical company CIS US and FDA approved on April 14, 2004.[L1469]
Categories: Compounds used in a research, industrial, or household settingSynonyms: DTP-AL-Glutamine
go.drugbank.com/drugs/DB00130ApprovedInvestigationalNutraceuticalA non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. … An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.
Segesterone acetate
go.drugbank.com/drugs/DB14583ApprovedSegesterone acetate is a steroidal progestin or synthetic progesterone and a 19-norprogesterone derivative with no CH3 group radical in position 6 [A37048]. … Food and Drug Administration (FDA) as the first and only contraceptive that provides an entire year of protection against unintended pregnancy while entirely under a woman's control.
Brentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigationalFood and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. … [L1737] Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexDecitabine
go.drugbank.com/drugs/DB01262ApprovedInvestigational[A215082, A215092] Among treatment options, nucleoside analogues such as decitabine and [azacitidine] integrate into cellular DNA and inhibit the action of DNA methyltransferases, leading to global hypomethylation … Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis.
Synonyms: DAC, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-s-triazin-2(1H)-oneDornase alfa
go.drugbank.com/drugs/DB00003ApprovedInvestigationalDornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. … Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology.
Elvitegravir
go.drugbank.com/drugs/DB09101ApprovedInvestigationalIt was FDA approved on August 27, 2012. On September 24, 2014, the FDA approved the single pill form of elvitegravir. … Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome and thereby blocks the formation of the HIV-1 provirus and resulting propagation
Fenoldopam
go.drugbank.com/drugs/DB00800ApprovedA dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
Categories: Dopamine D1 Receptor Agonists